NeuroSense Therapeutics Files 6-K Report
Ticker: NRSNW · Form: 6-K · Filed: Jun 17, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, registration-statement
TL;DR
NeuroSense Therapeutics filed a 6-K, incorporating prior exhibits into its S-8 and F-3 filings.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on June 17, 2024, reporting for the period ending December 31, 2023. The filing incorporates by reference exhibits 99.1, 99.2, and 99.3 into its existing registration statements on Form S-8 and Form F-3. The company is based in Herzliya, Israel.
Why It Matters
This filing updates the company's reporting status and incorporates previous exhibits into its active registration statements, which is relevant for ongoing securities offerings or compliance.
Risk Assessment
Risk Level: low — This is a routine reporting form that incorporates previously filed information, not announcing new material events.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- 001-41084 (company) — SEC File Number
- 333-262480 (company) — Form S-8 File Number
- 333-269306 (company) — Form F-3 File Number
- 333-260338 (company) — Form F-3 File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information required by foreign private issuers and to incorporate by reference exhibits 99.1, 99.2, and 99.3 into the registrant's existing registration statements on Form S-8 and Form F-3.
What is the reporting period for this Form 6-K?
The Conformed Period of Report is December 31, 2023.
Where is NeuroSense Therapeutics Ltd. located?
NeuroSense Therapeutics Ltd. is located at 11 HaMenofim Street, Building B, Herzliya, Israel.
Which registration statements are being updated by this filing?
This Form 6-K is incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File Nos. 333-269306 and 333-260338).
What type of company is NeuroSense Therapeutics Ltd. classified as by the SEC?
NeuroSense Therapeutics Ltd. is classified under Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
Filing Stats: 382 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2024-06-17 17:22:46
Filing Documents
- ea0207963-6k_neurose.htm (6-K) — 16KB
- ea020796301ex99-1_neurose.htm (EX-99.1) — 643KB
- ea020796301ex99-2_neurose.htm (EX-99.2) — 208KB
- ea020796301ex99-3_neurose.htm (EX-99.3) — 2KB
- 0001213900-24-053407.txt ( ) — 5703KB
- nrsn-20231231.xsd (EX-101.SCH) — 75KB
- nrsn-20231231_cal.xml (EX-101.CAL) — 36KB
- nrsn-20231231_def.xml (EX-101.DEF) — 283KB
- nrsn-20231231_lab.xml (EX-101.LAB) — 544KB
- nrsn-20231231_pre.xml (EX-101.PRE) — 291KB
- ea0207963-6k_neurose_htm.xml (XML) — 715KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: June 17, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3